Fig. 3.

Effects of cisplatin and CDD866 on muscle weight. Tibialis (a), gastrocnemius complex (b), and quadriceps (c). Values are expressed as means ± SEM (n = 6–8). Percent changes of muscle weight, normalized to initial body weight, were calculated in comparison to non-tumor control. * P < 0.05, ** P < 0.01 versus non-tumor control; + P < 0.05, ++ P < 0.01 versus non-tumor cisplatin; ## P < 0.01 versus CT-26 cisplatin